Evidence map›Paper›PMID 40122128›Full record

ArticleVirulence2025

Gut microbiome composition and metabolic activity in metabolic-associated fatty liver disease.

Daya Zhang, Qi Wang, Da Li, Shiju Chen, Jinrun Chen, Xuli Zhu, Feihu Bai

Abstract read
In one paragraph

Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Frontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daya ZhangThe Second School of Clinical Medicine, Hainan Medical University, Haikou, China.ORCID 0000-0001-6133-8919
Qi WangThe Second School of Clinical Medicine, Hainan Medical University, Haikou, China.
Da LiThe Second School of Clinical Medicine, Hainan Medical University, Haikou, China.
Shiju ChenThe Second School of Clinical Medicine, Hainan Medical University, Haikou, China.
Jinrun ChenDepartment of Gastroenterology, Otog Front Banner People 's Hospital, Otog Front Banner, China.
Xuli ZhuDepartment of Gastroenterology, Otog Front Banner People 's Hospital, Otog Front Banner, China.
Feihu BaiDepartment of Gastroenterology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.ORCID 0009-0005-4721-0130

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic Associated Fatty Liver Disease (MAFLD) impacts approximately 25% of the global population. Between April 2023 and July 2023, 60 patients with MAFLD, along with 60 age, ethnicity, and sex-matched healthy controls (HCs), were enrolled from the Inner Mongolia Autonomous Region, China. Analysis of gut microbiota composition and plasma metabolic profiles was conducted using metagenome sequencing and LC-MS. LEfSe analysis identified five pivotal species: Eubacterium rectale, Dialister invisus, Pseudoruminococcus massiliensis, GGB3278 SGB4328, and Ruminococcaceae bacteria. In subgroup analysis, Eubacterium rectale tended to increase by more than 2 times and more than double in the non-obese MAFLD group, and MAFLD with moderate hepatic steatosis (HS), respectively. Plasma samples identified 172 metabolites mainly composed of fatty acid metabolites such as propionic acid and butyric acid analogues. Ruminococcaceae bacteria have a strong positive correlation with β-alanine, uric acid, and L-valine. Pseudoruminococcus massiliensis has a strong positive correlation with β-alanine. Combinations of phenomics and metabolomics yielded the highest accuracy (AUC = 0.97) in the MAFLD diagnosis. Combinations of phenomics and metagenomics yielded the highest accuracy (AUC = 0.94) in the prediction of the MAFLD HS progress. Increases in Eubacterium rectale and decreases in Dialister invisus seem to be indicative of MAFLD patients. Eubacterium rectale may predict HS degree of MAFLD and play an important role in the development of non-obese MAFLD. Eubacterium rectale can generate more propionic acid and butyric acid analogues to absorb energy and increase lipid synthesis and ultimately cause MAFLD.

Indexed as

BacteriaFatty LiverGastrointestinal MicrobiomeAdultAgedCase-Control StudiesChinaFemaleHumansMaleMetabolomeMetabolomicsMetagenomeMetagenomicsMiddle AgedEubacterium rectaleintestinal microfloraMetabolic-associated fatty liver diseasemetabolitemetagenomeSCFA

Identifiers

PMID40122128
PMCPMC11959907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.